When NSAIDs such as diclofenac are used with anticoagulants, what is the main safety concern?

When NSAIDs such as diclofenac are used with anticoagulants, what is the main safety concern?

• A. No interaction
• B. Decreased efficacy
• C. Increased bleeding
• D. Increased renal excretion

Answer: (C)

The key idea is that combining NSAIDs with anticoagulants raises the risk of bleeding. NSAIDs like diclofenac inhibit an enzyme (COX-1) that helps platelets clump together, so they impair primary hemostasis. They also irritate the stomach lining and can cause ulcers, which increases the chance of GI bleeding. Anticoagulants, on the other hand, slow down the blood’s ability to clot by affecting the coagulation cascade. When both drugs are used together, you get two pathways toward bleeding: impaired platelet plug formation from the NSAID and reduced clot formation from the anticoagulant. This combination makes even minor injuries more likely to bleed and can lead to major bleeding, especially in the GI tract. So the main safety concern is increased bleeding. The other options don’t capture that dual, bleeding-centric risk: the interaction isn’t about no interaction, it isn’t about decreased efficacy of the anticoagulant, and increased renal excretion isn’t the central issue here. If this combination is necessary, careful risk assessment and strategies to minimize bleeding risk should be considered.

The key idea is that combining NSAIDs with anticoagulants raises the risk of bleeding. NSAIDs like diclofenac inhibit an enzyme (COX-1) that helps platelets clump together, so they impair primary hemostasis. They also irritate the stomach lining and can cause ulcers, which increases the chance of GI bleeding. Anticoagulants, on the other hand, slow down the blood’s ability to clot by affecting the coagulation cascade. When both drugs are used together, you get two pathways toward bleeding: impaired platelet plug formation from the NSAID and reduced clot formation from the anticoagulant. This combination makes even minor injuries more likely to bleed and can lead to major bleeding, especially in the GI tract.

So the main safety concern is increased bleeding. The other options don’t capture that dual, bleeding-centric risk: the interaction isn’t about no interaction, it isn’t about decreased efficacy of the anticoagulant, and increased renal excretion isn’t the central issue here. If this combination is necessary, careful risk assessment and strategies to minimize bleeding risk should be considered.